Skip to content
Peptide Atlas
All peptides

SNAP-8

Tier 3 · Reported use
Also known as Acetyl octapeptide-3 · Acetyl glutamyl heptapeptide-1

The strongest source tags present are Tier 1 (human clinical/RCT), but these largely concern the parent hexapeptide Argireline (Acetyl Hexapeptide-8) and treatment-duration observations rather than independent randomized trials of SNAP-8 itself. For SNAP-8 specifically, nearly all efficacy data derive from Lipotec/Lubrizol proprietary in-vitro and cosmetic testing. A 2025 review rated the evidence for topical facial-muscle synaptic inhibition as largely hypothetical, and some sources assert no independent peer-reviewed human trials of SNAP-8 exist. The tier is set to reflect the strongest tags present while noting this substantial limitation.

Half-life
Not recorded
Routes
Topical
Goals
Cosmetic / anti-aging skincare · Wrinkle reduction (topical)
Cost / mg
Not recorded

How it works

SNAP-8 is a lab-made cosmetic peptide, an extended version of Argireline, designed to relax the small facial muscles that create expression lines. It is proposed to imitate part of a natural protein (SNAP-25) involved in nerve signaling, competing with that protein so the nerve releases less of the chemical (acetylcholine) that tells muscles to contract. The idea is that softer muscle contractions mean shallower dynamic wrinkles like crow's feet and forehead lines. Unlike Botox, it is described as a reversible competitor that relaxes rather than paralyzes muscles, so effects are subtler and fade when you stop using it. A major open question is whether such a large molecule can actually penetrate skin deeply enough to reach nerves.

Overview

Overview

SNAP-8 (INCI: Acetyl Octapeptide-3 / Acetyl Glutamyl Heptapeptide-1; also listed by one source as acetyl glutamyl heptapeptide-3) is a synthetic acetylated octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, molecular formula C41H70N16O16S and a molecular weight of approximately 1,075 Da (CAS 868844-74-0, PubChem CID 76283482).

It was developed by Lipotec S.A.U. (Barcelona, Spain), now part of Lubrizol Life Science (acquired by Lubrizol/Berkshire Hathaway in 2012), as a second-generation follow-up to Argireline (Acetyl Hexapeptide-8/-3). SNAP-8 elongates the Argireline hexapeptide by two additional C-terminal amino acids (alanine and aspartic acid), a modification intended to enhance binding affinity and anti-wrinkle activity.

Proposed Mechanism

SNAP-8 is proposed to mimic the N-terminal domain of SNAP-25 and act as a reversible competitive inhibitor of SNARE complex assembly. By competitively displacing endogenous SNAP-25, it is thought to reduce vesicular fusion and decrease acetylcholine release, relaxing the facial muscles that produce dynamic expression lines. Importantly, and unlike botulinum toxin, it does not cleave SNAP-25 or cause muscle paralysis — it is described as relaxing muscles without freezing them.

Intended Use

SNAP-8 targets dynamic wrinkles caused by repeated facial muscle contraction — glabellar lines, crow's feet, and forehead lines — with little direct effect on static wrinkles. It is used exclusively as a topical cosmetic ingredient and is not an injectable.

Efficacy Evidence

  • In manufacturer (Lipotec/Lubrizol) in-vivo cosmetic testing, a 10% SNAP-8 formulation applied twice daily for 28 days reduced periorbital wrinkle depth by up to approximately 63% (figures cited include 63.18% and 63.13%) versus vehicle/baseline.
  • Other reported figures include an average wrinkle-depth reduction of ~35% (max approaching 60% in some areas) after 28-30 days, ~38% at 28 days, and ~21% at 7 days.
  • SNAP-8 is reported to be about 30% more potent than Argireline in head-to-head cosmetic comparisons, and in vitro assays report it inhibits SNARE assembly roughly 2-3x more potently than Argireline on a molar basis.
  • Visible effects typically require 20-60 days of continuous use, with microtopography improvements measured at 20-day intervals; effects are temporary and reverse on discontinuation.

Important Caveats

The published efficacy base is limited primarily to Lipotec/Lubrizol proprietary testing rather than independent peer-reviewed randomized clinical trials. A 2025 comprehensive review concluded that evidence for inhibition of synaptic transmission in facial muscles via topical application remains limited and largely hypothetical, and some sources assert that no independent human clinical trials or peer-reviewed human data exist for SNAP-8 (contrasting with roughly 15 years of human data for Argireline). Independent estimates of real-world improvement (~10-20%) are considerably more modest than manufacturer figures (~30-63%).

Much of the direct mechanistic data (chromaffin-cell exocytosis, SNARE inhibition, blepharospasm exploration) concerns related peptides — SNAP-25-derived peptides and Acetyl Hexapeptide-8 (Argireline) — rather than the SNAP-8 octapeptide itself.

Skin penetration is a key open question: at ~1,075 Da, SNAP-8 is about 18.6% larger than Argireline (~889 Da) and far exceeds the ~500 Da threshold typically permitted by the skin barrier. Several sources question whether it can reach the neuromuscular junction without penetration enhancers, and Lipotec's own transepidermal flux studies reportedly show no penetration advantage over Argireline — even as some marketing describes it as 'designed to penetrate deeper.'

What the research shows

2 findings extracted from the 1 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

How it works

Based on 1 human trial finding.

  • human trialAcetyl Hexapeptide-8 (AH8) is a competitive SNAP25 inhibitor1

What people use it for

Based on 1 human trial finding.

  • human trialTopical Acetyl Hexapeptide-8 (AH8) was explored for safety and efficacy as a potential new therapy in BSP1

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Nearly all efficacy data come from the manufacturer, not independent peer-reviewed trials.

Multiple sources note the published evidence base is limited to Lipotec/Lubrizol proprietary in-vitro and cosmetic testing; a 2025 review called facial-muscle synaptic inhibition via topical application 'largely hypothetical', and evidence was rated Grade C strength. Independent randomized controlled trials for SNAP-8 are reported as absent.

Contested

Whether SNAP-8 can penetrate skin deeply enough to work is disputed.

SNAP-8 (~1,075 Da) far exceeds the ~500 Da skin-barrier threshold; SNAP-8 (Acetyl Octapeptide-3): Research Evidence & Safety Profile | PeptideInsight, Snap-8: Research, Evidence & Safety | Peptidings, SNAP-8 Research Studies and Evidence | Peptide Protocol Wiki and Snap-8 Peptide: Anti-Wrinkle Octapeptide Complete Guide - SeekPeptides question whether it reaches the neuromuscular junction, and Snap-8: Research, Evidence & Safety | Peptidings says Lipotec's own flux studies show no penetration advantage over Argireline. Meanwhile Snap-8 Peptide: Anti-Wrinkle Octapeptide Complete Guide - SeekPeptides markets it as 'designed to penetrate deeper' and Does Snap-8 reduce wrinkles - Peptides Lab UK claims a well-characterised, accumulating body of evidence — an unresolved tension.

Other

Direct mechanistic data are for related peptides, not SNAP-8 itself.

The chromaffin-cell exocytosis and SNARE inhibition data cited come from SNAP-25-derived/hexapeptide (Argireline) studies; SNAP-8 Dosage, Half-Life & Research | Peptigo explicitly notes that direct mechanistic data specific to the SNAP-8 octapeptide itself remain limited, and Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of .../SNAP-8 Research Studies and Evidence | Peptide Protocol Wiki evidence concerns Acetyl Hexapeptide-8 rather than SNAP-8.

Single source

Injectable-use safety statements come from isolated sources.

SNAP-8 Injection: How to Use, Dosing & What the ... alone notes no large-scale human safety trial exists for injected SNAP-8 and flags injection risks, while Snap-8: Research, Evidence & Safety | Peptidings states SNAP-8 is used only topically, never as an injectable; sources do not otherwise support injectable use.

Inconsistency

The strongest human wrinkle data comes from Argireline, not from SNAP-8 itself.

The one peer-reviewed clinical paper attached here, "Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of ...", tested Acetyl Hexapeptide-8 (Argireline) as a SNAP-25 inhibitor for blepharospasm — not the octapeptide SNAP-8. For SNAP-8 specifically, independent reviews describe the published clinical evidence as limited primarily to Lipotec/Lubrizol proprietary cosmetic testing rather than independent randomized trials, with one review reporting that no clinical trials or peer-reviewed human efficacy studies of SNAP-8 have been published and that the randomized, placebo-controlled studies commonly cited (Blanes-Mira 2002 and Wang 2013) actually evaluated Argireline. A 2025 comprehensive review concluded that evidence for inhibition of synaptic transmission in facial muscles via topical application 'remains limited and largely hypothetical,' and one profile grades the overall evidence as Grade C, resting on in-vitro and cell-based work rather than human studies of SNAP-8.

Inconsistency

Published figures for how much SNAP-8 a finished skincare product actually contains vary enormously, because some numbers describe the dilute peptide solution and others the tiny…

SNAP-8 is supplied to formulators as 'Peptide Solution C,' which is almost entirely water and contains only about 0.05% actual peptide. Products then incorporate this solution at roughly 3–10%. Doing the arithmetic, the pure peptide content of a finished cream or serum works out to only about 0.0015–0.005% — a few thousandths of a percent. One vendor-published source instead describes SNAP-8 as used at a '3–5% solution diluted to 0.5–1% in the finished product,' figures that are roughly 100 to 1,000 times higher; those almost certainly refer to the amount of peptide solution (or a differently defined concentrate) rather than pure peptide. The practical point for a reader is that the amount of actual peptide delivered is very small, and any single percentage figure is meaningless unless it states whether it refers to the peptide solution or to the pure peptide.

Inconsistency

The claim that SNAP-8's wrinkle-reduction and duration-of-effect figures rest on randomized controlled trials is not backed by any independent trial.

The reference SNAP-8 — Dosage, Half-Life & Research Reference lists the "evidence basis" for its dosing and duration-of-effect figures as "RCT, in vitro skin penetration studies." But independent reviews find no published randomized controlled trials for SNAP-8 specifically. Snap-8: Research, Evidence & Safety reports "zero clinical trials" and that no independent laboratory has tested SNAP-8 in human subjects; SNAP-8 Peptide: Research, Dosage & Wrinkle Benefits states "No independent peer-reviewed RCTs published as of 2026; most evidence is from cosmetic ingredient supplier studies"; and SNAP-8 (Acetyl Octapeptide-3): Research Evidence & Safety Profile notes the efficacy data is "limited primarily to Lipotec/Lubrizol proprietary data." The widely repeated ~63% wrinkle-depth figures trace to manufacturer technical literature rather than independent randomized trials.

What you may have heard

The "potency similar to botulinum toxin A" comparison comes from an isolated-cell assay and does not mean the topical peptide matches injectable Botox.

The claim traces to the Blanes-Mira et al. 2002 study on Argireline, the hexapeptide parent of SNAP-8, in which the peptide inhibited catecholamine (neurotransmitter) release with a potency described as similar to botulinum neurotoxin type A in in-vitro assays — but the same study noted substantially lower efficacy, and it was a manufacturer-sponsored study measured on Argireline rather than SNAP-8. This is a comparison in isolated cells, not a head-to-head clinical comparison of the topical peptide against injectable botulinum toxin.

What you may have heard

'2–3x more potent than Argireline' rests on a single in-vitro source that elsewhere asserts no human data exist.

Claim 12 is sourced only to Snap-8: Research, Evidence & Safety | Peptidings, which simultaneously argues no human/clinical evidence for SNAP-8 exists. Presenting a precise molar-potency multiple alongside a 30% clinical-potency figure gives a false sense of quantitative certainty from divergent, low-tier data.

What you may have heard

Much of the clinical trial evidence cited for SNAP-8 is actually from studies of a different, related peptide called Argireline, not SNAP-8 itself.

The strongest human study linked to this peptide family — a pilot trial of topical Acetyl Hexapeptide-8 (Argireline) explored for blepharospasm — tested Argireline, the shorter parent peptide, rather than SNAP-8. No independent randomized controlled trials or peer-reviewed human efficacy studies of SNAP-8 itself have been published; the widely quoted wrinkle-reduction numbers come from the manufacturer's own cosmetic testing. Argireline has roughly fifteen years of human data behind it, while SNAP-8 has essentially none of its own, so any impression of a strong clinical evidence base for SNAP-8 largely borrows from work on the older peptide.

Using it with other compounds

Check a stack
  • SYN-AKEComplementary

    May be complementary

    Both soften dynamic wrinkles by quieting the neuromuscular junction, but from opposite sides of the synapse: SNAP-8 inhibits the presynaptic SNARE machinery that releases acetylcholine, whereas SYN-AKE blocks the postsynaptic nicotinic receptor that would receive it. Because they interrupt the same muscle-contraction signal at two different steps, combining them can give a more complete relaxation effect than either alone.

    Tier 3Largely anecdotal — commonly discussed

    Timing Topical use; can be layered in the same routine.

    Shares acetylcholine pathway

  • ArgirelineSame mechanism

    Worth caution

    SNAP-8 is essentially an extended version of Argireline — both are synthetic mimics of the SNAP-25 protein that competitively interfere with SNARE complex assembly to reduce acetylcholine release at facial muscles. Because they hit the exact same target by the same mechanism, layering both is redundant rather than additive; you are paying for two peptides doing one job. Choose one rather than stacking.

    Tier 4Theoretical — not established

    Shares acetylcholine pathway

  • LeuphasylComplementary

    May be complementary

    SNAP-8 is an extended Argireline that blocks SNARE-complex assembly to reduce acetylcholine release, while Leuphasyl reduces the same release presynaptically through enkephalin/Gi signaling. Different molecular handles on the same neuromuscular relaxation goal, so they can complement each other in an anti-wrinkle topical rather than being redundant.

    Tier 3Largely anecdotal — commonly discussed

    Timing Topical; apply together.

    Shares acetylcholine pathway

Safety and side effects

Safety & Tolerability

As a topical cosmetic ingredient, SNAP-8 is generally described as well tolerated. Reported skin irritation is minimal; mild irritation and transient redness are described as rare, and no widespread allergic reactions have been reported. Suppliers report no systemic neuromuscular effects from topical use(vendor claim).

Regulatory Status

SNAP-8 is classified as a cosmetic ingredient (EU CosIng listed, used in US cosmetics) and has not received drug approval in any jurisdiction. It is not FDA-approved, is handled as a research compound in that context, and has no FDA-registered injectable application. EU regulatory assessments considered it safe for cosmetic use.

Systemic Exposure

Systemic absorption of topical SNAP-8 is considered negligible, with the peptide reported to remain in the stratum corneum and epidermis; no reliable human pharmacokinetic half-life has been established.

Contraindications & Cautions

  • Relative contraindications include active skin infections or open wounds at the application site.
  • There is a theoretical (undocumented) concern for people with neuromuscular disorders.
  • Injectable use is not supported: one source notes no large-scale human safety trial exists for injected SNAP-8 and flags injection risks (infection, local irritation); another source states SNAP-8 is used only topically and never as an injectable.

Additional Notes

An in-vitro concentration-dependent antiproliferative effect was observed for the related hexapeptide argireline (IC50 ~10 mg/mL); this figure pertains to the 6-amino-acid analogue rather than SNAP-8 itself. An IC50 of ~10 mg/mL is an extremely high concentration — orders of magnitude beyond anything skin would encounter from a topical product — so it effectively indicates negligible cytotoxic relevance rather than a meaningful safety concern. Because much safety framing rests on manufacturer and expert-opinion sources rather than independent human trials, the overall human safety database specific to SNAP-8 remains limited.

Reconstitution and handling

Formulation & Concentration

SNAP-8 is a topical ingredient — not reconstituted for injection. It is commercially supplied as SNAP-8 Peptide Solution C, a standardized solution containing 0.05% active peptide in water.

  • In finished topical cosmetic formulations, the supplier's peptide solution is typically used at 3-10% (some sources cite 2-10%; commercial products commonly 5-10%).
  • One source describes typical use at 3-5% solution diluted to 0.5-1% in the finished product.
  • The pure peptide content of finished products is very low (roughly 0.0015-0.005%).
  • Applied to expression-line areas twice daily.

Formulation Types

Common vehicles include oil-in-water emulsions, serums, and creams.

Stability & Storage

  • Peptides are sensitive to light, heat, and pH and require proper formulation with preservatives and appropriate storage; refrigeration extends shelf life.
  • The methionine residue in SNAP-8 is susceptible to oxidation in formulation, which may reduce efficacy — a formulation stability consideration.

Duration of Use

Visible effects generally require about 20-60 days of continuous application, with wrinkle-depth reduction reported by day 20-28. Because effects are temporary and reverse upon discontinuation, continuous application is needed to maintain results.

Analytical Note

A validated LC-MS/MS method exists for acetyl octapeptide-3 quantification, applicable to microneedle patch delivery system analysis.

Sources

Ordered by evidence quality — the strongest first.

  1. Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov

See something wrong or out of date on this page? Report it.